[go: up one dir, main page]

WO1996007739A3 - Interleukin-1 type 3 receptors - Google Patents

Interleukin-1 type 3 receptors Download PDF

Info

Publication number
WO1996007739A3
WO1996007739A3 PCT/US1995/012037 US9512037W WO9607739A3 WO 1996007739 A3 WO1996007739 A3 WO 1996007739A3 US 9512037 W US9512037 W US 9512037W WO 9607739 A3 WO9607739 A3 WO 9607739A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
interleukin
type
expressing
nucleic acid
Prior art date
Application number
PCT/US1995/012037
Other languages
French (fr)
Other versions
WO1996007739A2 (en
Inventor
Timothy W Lovenberg
Tilman Oltersdorf
Chen W Liaw
William Clevenger
Errol B Desouza
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Priority to EP95934482A priority Critical patent/EP0779923A2/en
Priority to AU36805/95A priority patent/AU705595B2/en
Priority to JP8509726A priority patent/JPH10508743A/en
Publication of WO1996007739A2 publication Critical patent/WO1996007739A2/en
Publication of WO1996007739A3 publication Critical patent/WO1996007739A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides isolated nucleic acid molecules encoding soluble and membrane bound forms of Interleukin-1 Type 3 receptors, as well as recombinant expression vectors and host cells suitable for expressing such receptors.
PCT/US1995/012037 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors WO1996007739A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95934482A EP0779923A2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors
AU36805/95A AU705595B2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors
JP8509726A JPH10508743A (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30395794A 1994-09-09 1994-09-09
US08/303,957 1994-09-09

Publications (2)

Publication Number Publication Date
WO1996007739A2 WO1996007739A2 (en) 1996-03-14
WO1996007739A3 true WO1996007739A3 (en) 1996-04-18

Family

ID=23174426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012037 WO1996007739A2 (en) 1994-09-09 1995-09-11 Interleukin-1 type 3 receptors

Country Status (5)

Country Link
EP (1) EP0779923A2 (en)
JP (1) JPH10508743A (en)
AU (1) AU705595B2 (en)
CA (1) CA2199609A1 (en)
WO (1) WO1996007739A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
AR017518A1 (en) * 1997-10-15 2001-09-12 Schering Corp AN IL-1RD9 ISOLATED OR RECOMBINANT POLYPEPTIDE, A FUSION PROTEIN, A COMPOSITION, A KIT, A METHOD TO PRODUCE AN ANTIBODY, A COMPOSITION OF THE MATTER, A SUBSTANTIALLY PURE OR ISOLATED POLYPEPTIDE, A COMPOSITE TO A RECOVERED COMPOSITION CODE A PROTEIN
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2804028B1 (en) * 2000-01-21 2004-06-04 Merial Sas IMPROVED DNA VACCINES FOR PENSION ANIMALS
WO2001057219A2 (en) * 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DE60138403D1 (en) 2000-09-26 2009-05-28 Crucell Holland Bv ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST
KR101021387B1 (en) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. Means and methods for producing adenovirus vectors
EP3823989A2 (en) 2018-07-16 2021-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host
EP0623674A1 (en) * 1987-11-25 1994-11-09 Immunex Corporation Interleukin-1 receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623674A1 (en) * 1987-11-25 1994-11-09 Immunex Corporation Interleukin-1 receptors
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7105346B2 (en) 1995-06-15 2006-09-12 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Also Published As

Publication number Publication date
AU3680595A (en) 1996-03-27
JPH10508743A (en) 1998-09-02
WO1996007739A2 (en) 1996-03-14
AU705595B2 (en) 1999-05-27
EP0779923A2 (en) 1997-06-25
CA2199609A1 (en) 1996-03-14

Similar Documents

Publication Publication Date Title
WO1996007739A3 (en) Interleukin-1 type 3 receptors
CA2258502A1 (en) Modified factor viii
WO2000005367A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU4833897A (en) Glial mitogenic factors, their preparation and use
EP1559776A3 (en) Non-toxic, non-toxigenic, non-pathogenic Fusarium expression system and promoters and terminators for use therein
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
EP0804609A4 (en) NOVEL p53 RESPONSE GENES
WO1998021343A8 (en) Genes encoding telomerase proteins
WO1995034651A3 (en) Corticotropin-releasing factor2 receptors
WO1996023066A3 (en) Prostaglandin receptor, dp
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
CA2336261A1 (en) Cyclin e2 genes and proteins
CA2173102A1 (en) Dna sequence coding for a bmp receptor
CA2204151A1 (en) Cdna encoding a bmp type ii receptor
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO1994019464A3 (en) Human dna sequence encoding a kidney atp-dependent potassium channel
AU3711597A (en) A novel galanin receptor
WO1999009182A3 (en) Rab proteins
AU1183200A (en) Novel gene encoding brain-specific membrane protein
WO1999043802A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2199609

Country of ref document: CA

Ref country code: CA

Ref document number: 2199609

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995934482

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995934482

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995934482

Country of ref document: EP